Story perspectives

Study Finds Pharma-Linked Representatives at 40% FDA Meetings

By Drooid · Oct 21, 2026, 11:42 PM UTC · How we work

Summary

Story summary

A new study found FDA panels include patient or consumer representatives tied to pharma-funded advocacy groups.
Nearly 40% of FDA meetings between 2013-2022 featured a pharma-funded advocacy representative.
One in ten FDA drug review meetings included a representative from an organization receiving sponsor funding.
Cardiovascular and renal committees had pharma-linked representatives in 52% of meetings, the highest share.
Nervous-system committees had pharma-tied consumer representatives in 89% of meetings.

1 of 1

Story summary

A new study found FDA panels include patient or consumer representatives tied to pharma-funded advocacy groups.
Nearly 40% of FDA meetings between 2013-2022 featured a pharma-funded advocacy representative.
One in ten FDA drug review meetings included a representative from an organization receiving sponsor funding.
Cardiovascular and renal committees had pharma-linked representatives in 52% of meetings, the highest share.
Nervous-system committees had pharma-tied consumer representatives in 89% of meetings.